|
|
|
|
| LEADER |
04976nam a22002775i 4500 |
| 001 |
000282415 |
| 005 |
20211029083226.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9780387766782
|
| 024 |
7 |
|
|a 10.1007/978-0-387-76678-2
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Drug Addiction :
|b From Basic Research to Therapy /
|c edited by Rao S. Rapaka, Wolfgang Sadée.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2008.
|
| 300 |
|
|
|a XXIII, 782 p. 197 illus., 1 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a General Topics -- DARPP-32 Mediates the Actions of Multiple Drugs of Abuse -- Drug Discovery From Natural Sources -- Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers -- Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse -- Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse -- Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets -- RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy -- Viewing Chemokines as a Third Major System of Communication in the Brain -- Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels -- Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells -- Transporters & Stimulants & Hallucinogens -- Role of Monoamine Transporters in Mediating Psychostimulant Effects -- Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse -- Serotonin Transporters: Implications for Antidepressant Drug Development -- Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy -- ? Opioids as Potential Treatments for Stimulant Dependence -- Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants -- Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors -- Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters -- Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions -- Receptors of Mammalian Trace Amines -- Drug Design: Nicotine, Opioids and Related Ligands -- The Role of Crystallography in Drug Design -- Opioid Peptide-Derived Analgesics -- Opioid Ligands with Mixed ?/? Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics -- Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP -- Kappa Opioid Antagonists: Past Successes and Future Prospects -- In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands -- Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies -- New Paradigms and Tools in Drug Design for Pain and Addiction -- Opioids: General -- Neuropeptide-Processing Enzymes: Applications for Drug Discovery -- CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier -- Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants -- Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development -- Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints -- Molecular Recognition of Opioid Receptor Ligands -- Role of Morphine’s Metabolites in Analgesia: Concepts and Controversies -- Mu Opioid Receptor Regulation and Opiate Responsiveness -- Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence -- Cannabinoid -- The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids -- Further Advances in the Synthesis of Endocannabinoid-Related Ligands -- Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials -- Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs -- Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids -- 2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook -- Endocannabinoid Mechanisms of Pain Modulation.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Rapaka, Rao S.
|e editor.
|
| 700 |
1 |
|
|a Sadée, Wolfgang.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|